Share on StockTwits

Shares of Tornier N.V. (NASDAQ:TRNX) reached a new 52-week high on Monday , Stock Ratings Network reports. The company traded as high as $22.49 and last traded at $22.42, with a volume of 63,183 shares. The stock had previously closed at $22.40.

TRNX has been the subject of a number of recent research reports. Analysts at TheStreet upgraded shares of Tornier N.V. from a “sell” rating to a “hold” rating in a research note on Friday. Separately, analysts at Barclays raised their price target on shares of Tornier N.V. from $23.00 to $26.00 in a research note on Thursday. They now have an “overweight” rating on the stock. Finally, analysts at Summer Street upgraded shares of Tornier N.V. from a “sell” rating to a “neutral” rating in a research note on Wednesday, May 7th. They now have a $18.00 price target on the stock, up previously from $16.00. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $20.29.

The stock’s 50-day moving average is $20. and its 200-day moving average is $19.3. The company’s market cap is $1.097 billion.

Tornier N.V. (NASDAQ:TRNX) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The company had revenue of $89.00 million for the quarter, compared to the consensus estimate of $80.41 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. Analysts expect that Tornier N.V. will post $-0.45 EPS for the current fiscal year.

In other Tornier N.V. news, CFO Shawn Mccormick sold 2,870 shares of the stock on the open market in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $21.42, for a total value of $61,475.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.